

***Clostridium perfringens* Enterotoxin is a Superantigen Reactive with Human T Cell Receptors V β 6.9 and V β 22**

By Paul Bowness,* Paul A. H. Moss,* Howard Tranter,† John I. Bell,* and Andrew J. McMichael*

From the *Molecular Immunology Group, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DU; and †Public Health Laboratory Service, Porton Down, Wilts SP4 0JG, UK

Summary

Candidate superantigens were screened for their ability to induce lysis of human histocompatibility leukocyte antigen class II-positive targets by human CD8⁺ influenza-specific cytotoxic T cell (CTL) lines. *Clostridium perfringens* enterotoxin (CPET) induced major histocompatibility complex unrestricted killing by some but not all CTL lines. Using "anchored" polymerase chain reactions, CPET was shown to selectively stimulate peripheral blood lymphocytes bearing T cell receptor V β 6.9 and V β 22 in five healthy donors. V β 24, V β 21, V β 18, V β 5, and V β 6.1-5 appeared to be weakly stimulated. Antigen processing was not required for CPET to induce proliferation. Like the staphylococcal enterotoxins, CPET is a major cause of food poisoning. These data suggest that superantigenic and enterotoxigenic properties may be closely linked.

The term superantigen (SA) has been applied to a group of bacterial and retroviral proteins that stimulate large numbers of T lymphocytes in a manner distinct from that of classical antigens (1). SA bind to the TCR V β chain of both CD4⁻ and CD8⁺ T cells (2), are mitogenic at nM concentrations, and do not require processing (3). SA bind MHC class II molecules selectively and with high affinity (4, 5), although they may also bind other ligands (6). Staphylococcal toxic shock syndrome toxin 1 (TSST) is implicated in toxic shock (7), and the staphylococcal enterotoxins (SE) are potent emetics, although it is not clear if their emetic action is a direct result of their superantigenic properties (8).

In this report we show that the 34-kD enterotoxin produced by *Clostridium perfringens* (CPET) is a superantigen with a novel specificity for human TCR V β chains.

Materials and Methods

Purification of Enterotoxins. SEA and SEB were purified from culture supernatants by dye ligand affinity chromatography as described (9). TSST was a gift from Rossalyn Brehm (Public Health Laboratory Service, Wilts, UK). CPET was purified as described previously (10).

Cytotoxic T Cell Lines and Clones. Influenza A virus-specific CTL lines were generated as described previously (11). Influenza A matrix peptide 57-68 was used to generate HLA A2-restricted CTL from donor JM (HLA A2 B15,51 Dr11) (11), and nucleoprotein (NP) 380-391 to generate HLA B27-restricted CTL (12) from donors GR (HLA A3,31 B27 DR4) and SD (HLA A2,32 B27,49 DR4 DQ8). CTL clones were obtained by limiting dilution. TCR usage of JM, GR, and SD CTL and clones (Bowness, P., and A. J.

McMichael, manuscript in preparation) was studied using the PCR as described below. CTL lysis assays were performed as described previously (11).

Proliferation Assays. PBMC from donor NW (HLA A3,31 B8,27 DR3,14) were cultured with APC in 96-well plates at 10⁵ cells/well. As APC autologous PBL were fixed with 0.025% glutaraldehyde for 90 s before adding 0.2 M lysine, washing three times, and irradiating (5,000 rad). APC were incubated for 2 h with purified protein derivative 1:200 (PPD 100,000 U/ml; Evans Medical, Langhurst, UK), CPET, SEB, or PHA at 5 μ g/ml before washing twice. After 5 d 1 μ Ci [³H]thymidine was added, cells were harvested after 6 h and counted by standard scintillation techniques.

Selection of Activated Lymphocytes. PBL, cultured for 72 h with CPET, TSST, or SEB at 100 ng/ml or PHA at 5 μ g/ml, were washed with PBS and incubated on ice with the mAb 23A9.3 (a gift of C. Mawas, Institut National de la Recherche Médicale, Marseille, France), specific for the IL-2 receptor (IL-2R). Lymphocytes bearing the IL-2 receptor were selected with magnetic beads coated with goat anti-mouse Ig (Dyna, Wirral, UK). Fresh unselected PBMC or IL-2R-selected PHA-stimulated PBMC were used as controls.

PCR Analysis of TCR V β Gene Usage. Total cellular RNA was extracted from CTL, unstimulated PBL, or activated lymphocytes. cDNA was synthesized using an oligo dT primer and anchored PCR (AnPCR) was performed using primers and conditions described previously (13). Amplification products were digested with BglII and NotI and cloned in a modified M13mp18 vector. Clones were either sequenced using T7 DNA polymerase or blotted onto nitrocellulose and hybridized with radiolabeled oligonucleotide probes for C β (5'-CGACTTCGGGTGGGAACAC); V β 6.9 (5'-TGGAGAAAGATCCCTTAG); V β 22 (5'-AGTGAATTTGATCCATCAG); and V β 24 (5'-AAAGCAGAAAGAAGTGT).






Figure 1. (a) Lysis of autologous target cells by JM and GR CTL in the presence of cognate peptide or bacterial toxins. Peptides (influenza matrix 57-68 for JM, nucleoprotein 380-391 for GR) were at 1 μ M. SEA, TSST, and CPET were at 25 nM. The E/T ratio was 2:1 for JM CTL, and 5:1 for GR CTL. (b) Lysis by SD CTL (HLA 2,3 B27,49 DR4 DQ8) of P815 cells transfected with HLA-B27 or of HLA mismatched target cells in the presence of influenza nucleoprotein peptide, CPET or SEB at 1 μ M. The E/T ratio was 1.5:1. (c) Lysis of autologous targets by GR CTL in the presence of influenza nucleoprotein 380-391 or CPET in the concentrations shown. The E/T ratio was 2:1.

Results and Discussion

CPET Facilitates Cytolysis by Some but Not All CTL. It has been demonstrated previously that CD8⁺ CTL with suitable TCR V β kill MHC class II-positive cells in the presence




Figure 2. Proliferation of NW PBL after 5-d culture with autologous irradiated APC, with or without prior glutaraldehyde fixation, incubated with PPD, CPET, SEB, or PHA (5 μ g/ml). Mean and SD of quadruplicate [³H]thymidine uptake estimations are shown.

ence of superantigens at nanomolar concentrations (2, 14, and P. Bowness, unpublished observations), regardless of their antigenic specificity. Influenza A-specific CD8⁺ oligoclonal CTL lines bearing different V β elements were used to screen potential superantigens. Such an experiment is shown in Fig 1 a. CPET induced killing of autologous targets in the absence of virus antigen by GR CTL (V β 24, 21, 7, 6, and 5), but not with JM CTL (V β 17). This suggested that CPET was a superantigen with specificity for the TCR V β expressed by GR CTL, but not JM CTL. Further experiments demonstrated that CPET-induced CTL killing is not MHC restricted. SD CTL (from which clones bearing V β 6, 7, and 21 were derived) killed only HLA B27 positive targets in the presence of cognate peptide but killed HLA-mismatched allogeneic B cell lines (but not P815 cells lacking MHC class II) in the




Figure 3. TCR V β usage of CPET-stimulated lymphocytes and PBL from WR. Numbers and percentages of sequenced clones of AnPCR products are shown. The V β 6 family is divided into V β 6.1-8 and V β 6.9. TCR V β usage of PBL from donor GR adapted from (21) with permission, and Rosenberg, W. R., unpublished data.

Table 1. TCR V β Usage of Lymphocytes Activated by PHA or Superantigens from Five Unrelated Donors

	C β		V β 6.9		V β 22		V β 24	
	No.	No.	Percent	No.	Percent	No.	Percent	
Donor 1								
CPET	141	34	24	20 [§]	14	9*	6	
PHA	146	8	6	5	3	5	4	
Donor 2								
CPET	80	23	30	14 [§]	18	5 [‡]	6	
PHA	325	26	8	18	6	5	2	
Donor 3								
CPET	53	5 [‡]	9	6 [‡]	11	ND		
PHA	102	2	2	1	1			
Donor 4								
CPET	201	24 [§]	12	17 [§]	9	ND		
PHA	137	3	2	1	1			
Donor 5								
CPET	244	17	7	14	6	ND		
SEB	366	3*	1	8 [‡]	2.2			
TSST	509	2*	0.4	0*	0			
PHA	435	4	1	1	0.2			

Represents TCR frequencies after culture of PBL for 72 h with CPET, PHA, SEB, or TSST; assigned by oligonucleotide probing of M13-cloned AnPCR products. The donor HLA types were: donor 1: A11,33 B35,65 DR1,4; donor 2: A3,31 B27 DR4; donor 3: A1,3 B7,8 DR3; donor 4: A2,29 B44 DR7; and donor 5: A1,2 B7,8.

* $p > 0.05$ compared with PHA.

[‡] $p < 0.05$ (Fisher's exact probability).

[§] $p < 0.005$.

^{||} $p < 0.0005$ (χ^2 with Yates' correction).

presence of CPET (Fig. 1 b). In contrast, two NP-specific HLA B27 restricted clones bearing V β 7.1 (derived from GR and SD CTL) were CPET unresponsive (data not shown). CPET induced killing at nanomolar concentrations (Fig. 1 a) that was dose dependent (Fig. 1 c), and caused modulation of CD3 from the CTL cell surface (data not shown).

Glutaraldehyde-fixed Cells Can Present CPET. PBMC proliferated in a dose-dependent manner when incubated with CPET at nanomolar concentrations (data not shown). Thymidine uptake was consistently 10-fold higher than with PPD or tetanus toxoid, peaked 2 d earlier (data not shown), and was not inhibited by glutaraldehyde fixation of APCs (Fig. 2), indicating that antigen processing is not required.

CPET Selectively Stimulates TCR V β 6.9 and V β 22. The V β distribution of CPET-stimulated lymphocytes from donor

WR, estimated by sequencing 40 M13-cloned AnPCR products of lymphocyte cDNA, was markedly different from that of unstimulated PBL (Fig. 3). 19 of 40 sequences were of the V β 6 family, and of these, 61% were V β 6.9 (14) (compared with only 39% of PBL V β 6 (W. Rosenberg, unpublished data). Four rare V β families: V β 18, 21, 22, and 24 (15), also appeared to be selectively stimulated by CPET. Of these, the most prominent was V β 22 (15), which made up 18% of sequences from CPET stimulated cells, as compared with < 2% of stimulated PBL. The stimulation of V β 6 and V β 21 was consistent with the cytolysis by GR and SD CTL (Fig. 1, a and b).

To confirm these findings using larger numbers, PBL from WR and four other unrelated donors were stimulated with CPET or PHA (and in one case also SEB and TSST), and after AnPCR recombinant M13 plaques were screened with oligonucleotide probes specific for the three TCR V β that appeared most strongly stimulated: V β 6.9, V β 22, and V β 24. The results are shown in Table 1. V β 6.9 and V β 22 were significantly stimulated by CPET in all five individuals tested ($p < 0.05$ as compared with PHA). V β 24 numbers were significantly increased after CPET stimulation in one of two donors tested. In the one individual tested, TSST stimulated neither V β 6.9 nor V β 22, but SEB was found to stimulate V β 22 to a low but significant extent.

AnPCR has not previously been used to study the TCR repertoire of SA-stimulated PBL. Unlike the "V region family specific" PCR techniques used previously (16), AnPCR gives quantitative information about all V β families and subfamilies. Hence, CPET is the only SA for which a complete profile of V β stimulation has been obtained. These findings also support the proposition that one SA may have different affinities for different V β elements (17).

It is possible that the novel SA characterized here is not CPET itself, but a contaminant of the preparations used. However, such contamination (which is not necessarily avoided by using recombinant preparations) is unlikely here because CPET was active at nanomolar concentrations and gave only a single visible band after SDS gel electrophoresis under non-denaturing conditions (10).

C. perfringens is the second or third most common cause of food poisoning in the USA (18), and the characteristic clinical features of abdominal pain and diarrhea are thought to be caused by CPET. CPET has also been implicated in cases of antibiotic-induced diarrhea, infantile diarrhea, and sudden infant death syndrome (reviewed in reference 19), as well as in the pathogenesis of rheumatoid arthritis (20). This study shows that CPET is a superantigen with novel TCR V β specificity. It is intriguing that although it has no obvious structural similarity with the staphylococcal enterotoxins, CPET shares both superantigenic and enterotoxigenic functions.

We thank William Rosenberg for supplying WR PBL V β 6.9 frequency details, and Mike Nicolle for assistance with proliferation assays.

This work was supported by the Medical Research Council (MRC) and The Wellcome Foundation. P. Bowness is an MRC Training Fellow. P. Moss is an MRC Clinician Scientist.

Address correspondence to Dr. P. Bowness, Molecular Immunology Group, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK.

Received for publication 9 December 1991 and in revised form 4 June 1992.

References

1. Kappler, J.W., A. Pullen, J. Callahan, Y. Choi, A. Herman, J. White, W. Potts, E. Wakeland, and P. Marrack. 1989. Consequences of self and foreign superantigen interaction with specific V beta elements of the murine TCR alpha beta. *Cold Spring Harbor Symp. Quant. Biol.* 1:401.
2. Herrmann, T., J.L. Maryanski, P. Romero, B. Fleischer, and H.R. MacDonald. 1990. Activation of MHC class I-restricted CD8⁺ CTL by microbial T cell mitogens. Dependence upon MHC class II expression of the target cells and V beta usage of the responder T cells. *J. Immunol.* 144:1181.
3. Kotb, M., G. Majumdar, M. Tomai, and E.H. Beachey. 1990. Accessory cell-independent stimulation of human T cells by streptococcal M protein superantigen. *J. Immunol.* 145:1332.
4. Herrmann, T., R.S. Accolla, and H.R. MacDonald. 1989. Different staphylococcal enterotoxins bind preferentially to distinct major histocompatibility complex class II isotypes. *Eur. J. Immunol.* 19:2171.
5. Karp, D.R., C.L. Teletski, P. Scholl, R. Geha, and E.O. Long. 1990. The alpha 1 domain of the HLA-DR molecule is essential for high-affinity binding of the toxic shock syndrome toxin-1. *Nature (Lond.)* 346:474.
6. Dohlsten, M., G. Hedlund, S. Segren, P.A. Lando, T. Herrmann, A.P. Kelly, and T. Kalland. 1991. Human major histocompatibility complex class II-negative colon carcinoma cells present staphylococcal superantigens to cytotoxic T lymphocytes: evidence for a novel enterotoxin receptor. *Eur. J. Immunol.* 21:1229.
7. Choi, Y., J.A. Lafferty, J.R. Clements, J.K. Todd, E.W. Gelfand, J. Kappler, P. Marrack, and B.L. Kotzin. 1990. Selective expansion of T cells expressing V β 2 in toxic shock syndrome. *J. Exp. Med.* 172:981.
8. Fleischer, B., H. Schrezenmeier, and P. Conradt. 1989. T lymphocyte activation by staphylococcal enterotoxins: role of class II molecules and T cell surface structures. *Cell. Immunol.* 120:92.
9. Brehm, R.D., H.S. Tranter, P. Hambleton, and J. Melling. 1990. Large-scale purification of staphylococcal enterotoxins A, B, and C2 by dye ligand affinity chromatography. *Appl. Environ. Microbiol.* 56:1067.
10. Reynolds, D., H.S. Tranter, and P. Hambleton. 1986. Scaled-up production and purification of *Clostridium perfringens* type
11. Gotch, F., J. Rothbard, K. Howland, A. Townsend, and A. McMichael. 1987. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. *Nature (Lond.)* 326:881.
12. Huet, S., D.F. Nixon, J. Rothbard, A.R.M. Townsend, S.A. Ellis, and A.J. McMichael. 1990. Structural homologies between two HLA B27 restricted peptides suggest residues important for interaction with HLA B27. *Int. Imm.* 2:311.
13. Moss, P.A.H., R.J. Moots, W.M.C. Rosenberg, S.J. Rowland-Jones, H.C. Bodmer, A.J. McMichael, and J.I. Bell. 1991. Extensive conservation of α and β chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide. *Proc. Natl. Acad. Sci. USA.* 88:8987.
14. Kimura, N., B. Toyonaga, Y. Yoshikai, R.-P. Du, and T.W. Mak. 1987. Sequences and repertoire of the human T cell receptor α and β variable region genes in thymocytes. *Eur. J. Immunol.* 17:375.
15. Ferradini, L., S. Roman-Roman, J. Azocar, H. Michalaki, F. Triebel, and T. Hercend. 1991. Studies on the human T cell receptor α/β variable region genes II. Identification of four additional V β subfamilies. *Eur. J. Immunol.* 21:935.
16. Choi, Y., B. Kotzin, L. Herron, J. Callahan, P. Marrack, and J. Kappler. 1989. Interaction of *Staphylococcus aureus* toxin "superantigens" with human T cells. *Proc. Natl. Acad. Sci. USA.* 86:8941.
17. Fleischer, B., R. Gerardy-Schahn, B. Metzroth, S. Carrel, D. Gerlach, and W. Kohler. 1991. An evolutionary conserved mechanism of T cell activation by microbial toxins: evidence for different affinities of T cell receptor-toxin interaction. *J. Immunol.* 146:11.
18. Horowitz, M.A. 1977. Specific diagnosis of foodborne disease. *Gastroenterology.* 73:375.
19. McClane, B.A., P.C. Hanna, and A.P. Wnek. 1988. Clostridium perfringens enterotoxin. *Microb. Pathog.* 4:317.
20. Olhagen, B., and I. Mansson. 1968. Intestinal *Clostridium perfringens* in rheumatoid arthritis and other collagen diseases. *Acta. Med. Scand.* 184:395.
21. Rosenberg, W.R., P.A.H. Moss, and J.I. Bell. 1992. Variation in human T cell receptor V beta and J beta repertoire: analysis using anchor PCR. *Eur. J. Immunol.* 22:541.